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ABSTRACT
Introduction: When insulin treatment is
started in patients with type 2 diabetes
mellitus (T2DM), there are many regimens
that control serum glucose levels to a normal
range. Basal-bolus insulin therapy is one of the
most effective treatments for improving
glycemic control to prevent the progression of
diabetic microvascular complications. This
study was conducted to determine whether
step-up insulin treatment with premixed
insulin aspart-30/70 (BIAsp 30) or lispro-50/50
(Mix50) in Japanese patients with type 2
diabetes mellitus could achieve better glycemic
control.
Methods: In this open label study, 72 insulin-
naı¨ve patients with poorly controlled T2DM
(HbA1c C8.4%), who had been taking oral
antidiabetic drugs for at least 12 months, were
randomized to receive BIAsp 30 or Mix50
therapy. Patients started treatment of a pre-
dinner injection of each type of insulin (Step 1).
At 16 ± 2 weeks, a pre-breakfast injection of each
type of insulin was added if HbA1c exceeded
7.4% (step 2). If patients had still not achieved
HbA1c\7.4% after an additional 16 ± 2 weeks, a
pre-lunch insulin injection was added (step 3).
Hypoglycemic episodes were also recorded.
Results: The cumulative percentages of subjects
who achieved HbA1c\7.4% were 36.1% (13/36)
for both Mix50 and BIAsp 30 in step 1, 62.9%
(23/36) for BIAsp 30 and 52.8% (19/36) for
Mix50 in step 2, and 66.7% (24/36) in BIAsp 30
and 72.2% (26/36) in Mix50 in step 3. The
achievement rates of HbA1c\7.4% were not
statistically different between the two groups. A
total of ten hypoglycemic episodes occurred in
this study. However, there were no severe
hypoglycemic episodes. All cases recovered by
taking glucose and drinking juice.
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Conclusion: Mix50 step-up treatment has a
clinical effect in achieving good glycemic
control equal to that of BIAsp 30 treatment.
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INTRODUCTION
When insulin treatment is started in patients
with type 2 diabetes mellitus (T2DM), there are
many regimens that control serum glucose
levels to a normal range. Basal-bolus insulin
therapy is one of the most effective treatments
for improving glycemic control to prevent the
progression of diabetic microvascular
complications [1]. This is because this
regimen can stimulate the secretion of
insulin from Islets of Langerhans at meal
times. However, basal-bolus regimen requires
four daily injections [2]. There are other
insulin treatments with fewer daily injections
which can achieve good glycemic control
similar to that achieved with basal-bolus
treatment. This is usually preferred by
patients with T2DM, as a smaller number of
daily injections can maintain their quality of
life and compliance [3]. In addition, research
by United Kingdom Prospective Diabetes
Study (UKPDS) strongly suggests that
intensive treatment prevented diabetic
microangiopathy complications independent
of insulin usage [4]; it is important to maintain
good glycemic control levels regardless of
multiple or single insulin injections. Recent
studies demonstrated that twice-daily
treatments with biphasic insulin aspart 70/30
(BIAsp 30) [5, 6] and premixed insulin lispro-
50/50 (Mix50) [3] could have equal effects on
glycemic control and convey better quality of
life than basal-bolus therapy in insulin-naı¨ve
patients. In addition, basal insulin (glargine)
plus oral treatment showed effects equivalent
to basal-bolus treatment [7]. Although these
regimens are not always effective for all
patients with (T2DM), a therapy with fewer
insulin injections might be favored by
physicians and patients.
The first 1-2-3 study was performed in the
United States [8]. It demonstrated the efficacy of
step-up treatment using premixed insulin BIAsp
30, and the practicality of once-daily injection
of BIAsp 30 was shown. In addition, twice-daily
injection treatment of BIAsp 30, which is used
widely [9], was shown to have beneficial effects
on glycemic control in a study by Valensi et al.
[9]. Subsequently, a similar 1-2-3 study
performed in Japan demonstrated that BIAsp
30 step-up therapy was a safe, simple therapy
that could achieve better glycemic control [10].
Overall, BIAsp 30 step-up therapy has
demonstrated efficacy as a continuing insulin
treatment to control glycemic levels regardless
of ethnicity.
On the other hand, Mix50 containing 50%
lispro and 50% neutral protamine lispro (NPL)
is widely used as a twice-daily insulin regimen
[11]. The regimen of premixed insulin Mix50
administered three times daily before meals
can maintain good glucose control compared
with twice-daily injection of humulin 30/70
insulin treatment [12], or with basal plus oral
antidiabetic drug (OAD) treatment in insulin-
naı¨ve patients with T2DM [13]. However, the
beneficial effects of step-up therapy using
Mix50 have not been clarified. Therefore, the
present study was conducted to determine
whether Japanese patients with type 2
diabetes mellitus could achieve better
glycemic control with step-up insulin
treatment with premixed insulin Mix50 than
with BIAsp 30.
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METHODS
Subjects
Seventy-two insulin-naı¨ve outpatients with
poorly controlled T2DM (glycated hemoglobin
A1c [HbA1c] C8.4%) aged over 20 years were
enrolled. They had been taking OADs for at
least 12 months and were randomized to receive
BIAsp 30 or Mix50 therapy. Patients with a
history of stroke or a cardiovascular event were
excluded. Concomitant treatment was stable
and maintained unchanged as much as possible
throughout the study period. This study was
performed at four hospitals (Tochigi). The study
protocol was approved by the institutional
review board of Dokkyo Medical University
Hospital. All procedures followed were in
accordance with the ethical standards of the
responsible committee on human
experimentation (institutional and national)
and with the Helsinki Declaration of 1975, as
revised in 2000 and 2008. Informed consent was
obtained from all patients for being included in
the study. All HbA1c data are shown in National
Glycohemoglobin Standardization Program
(NGSP) values.
Study Design
Patients were randomized by envelope method
to two groups: BIAsp 30 or Mix50 group. An
HbA1c target of 7.4% was set to minimize the
attrition rate and avoid rapid glycemic control
improvement, which may have occurred as a
result of patients with diabetic complications
being included in this study (this HbA1c value
corresponded to 7.0% in Japan Diabetes Society
[JDS] values). Patients started one injection of 6
units of each type of insulin 15 min before
dinner. Patients were instructed not to titrate
insulin units by patient themselves to ensure an
accurate evaluation. Insulin was decreased by 2
units in the event of morning fasting plasma
glucose (FPG) \80 mg/dl and increased insulin
amounts 2 units in case of morning FPG
[150 mg/dl at every visit (step 1). At 16 weeks,
a pre-breakfast injection of 6 units of each type
of insulin was added if HbA1c exceeded 7.4%.
Insulin was decreased by 2 units in the event of
pre-lunch FPG \80 mg/dl and increased by 2
units in the event of re-lunch FPG [150 mg/dl
at every visit (step 2). Any oral insulin secreting
drugs used during step 1 were discontinued
before the patient entered step 2. If patients had
still not achieved HbA1c \7.4% after an
additional 16 weeks, a pre-lunch insulin
injection of 6 units was added. Insulin was
decreased by 2 units in the event of pre-dinner
FPG \80 mg/dl and increased by 2 units in the
event of pre-dinner FPG [150 mg/dl at every
visit (step 3). The attending physicians
determined the insulin dosage every 4 weeks
to achieve HbA1c \7.4% and to avoid
hypoglycemic episodes. HbA1c levels, fasting
blood glucose, insulin dosage, body weight,
body mass index (BMI), and hypoglycemic
episodes were investigated at every visit.
Dietary education on diabetes was performed
within 3 months before starting insulin
treatment. HbA1c levels were determined
using high-performance liquid
chromatography (HPLC: Hi-AUTOA1c,
HA8150, Arkray Inc., Kyoto, Japan); all HbA1c
data are shown in NGSP values.
Statistical Analysis
All data were analyzed with JMP7 Japanese
version analytic software (SAS Japan, Tokyo,
Japan). The results are presented as the
mean ± standard deviation (SD). To compare
the two groups we carried out unpaired t test or
the Mann–Whitney U test for continuous
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variables and the v2 test or Fisher test for
qualitative variables. Two-tailed P values less
than 0.05 were considered significant.
RESULTS
Seventy-two patients with T2DM were enrolled
in this study. Patient baseline characteristics are
shown in Table 1. No significant differences in
any parameters at baseline were seen between
BIAsp 30 and Mix50 groups (Table 1). Sixty-four
patients completed this study, and eight
patients (four in BIAsp 30 and four in Mix50
group) refused to the increasing number of
insulin injections required to proceed from step
2 to step 3.
Glycemic Control
The cumulative percentage of subjects who
achieved HbA1c \7.4% was 36.1% (13/36) for
both Mix50 and BIAsp 30 in step 1. The values
were 63.9% (23/36) for BIAsp 30 and 52.8% (19/
36) for Mix50 in step 2, and 75% (24/32) for
BIAsp 30 and 81.3% (26/32 for Mix50 in step 3
(Fig. 1). The cumulative achievement rates of
HbA1c were not statistically different between
the two groups. Next, among all included
patients, 36.1% (13/36) in step 1, 43.5% (10/
23) in step 2, and 11.1% (1/9) in step 3 achieved
the target HbA1c \7.4% in the BIAsp 30 group,
while 36.1% (13/36) in step 1, 26.1% (6/23) in
the step 2, and 53.9% (7/13) in step 3 achieved
the target HbA1c \7.4% in the Mix50 group.
The HbA1c levels of 9.9 ± 1.7% at the
baseline of the study significantly decreased to
7.8 ± 1.0% after 16 weeks (completion of step-
1), 7.8 ± 1.0% after 32 weeks (completion of
step-2), and 8.2 ± 0.9% after 48 weeks
Table 1 Patient baseline characteristics, diabetic control,
and treatment types
BIAsp30 Mix50 P value
Number (male/female) 36 (14/22) 36 (15/21) 0.810
Age (years) 61.6 ± 13.0 63.4 ± 11.6 0.561
BMI (kg/m2) 24.4 ± 5.8 24.5 ± 4.3 0.783
Diabetic duration (years) 11.4 ± 8.5 10.7 ± 6.8 0.896
Blood HbA1c (%) 9.9 ± 1.7 9.6 ± 1.6 0.353
Smoking (n) 6 7 0.759
Complication (n)
Retinopathy 17 17 1.000
Nephropathy 18 15 0.478
(Urinary albumin excretion
ratio[30 mg/Cr)
Neuropathy 10 12 0.609
Hypertension 14 13 0.808
Hyperlipidemia 12 12 1.000
Medication (n)
SU 4 4 1.000
SU ? alpha-GI 3 4 0.691
SU ? TZ 3 4 0.691
SU ? MET 3 4 0.691
SU ? alpha-GI ? TZ 1 3 0.303
SU ? alpha-GI ? MET 5 5 1.000
alpha-GI 6 5 0.743
alpha-GI ? TZ 1 1 1.000
alpha-GI ? Glinide 1 0 0.341
alpha-GI ? Glinide ? TZ 0 2 0.151
Glinide 3 0 0.077
MET 4 2 0.394
TZ 2 2 1.000
Values are given as mean ± SD unless otherwise stated
Alpha-GI glucosidase inhibitor, BIAsp30 premixed insulin aspart-30/70,
BMI body mass index, MET metformin, Mix50 lispro-50/50,
SD standard deviation, SU sulfonylurea, TZ thiazolidine
Fig. 1 Cumulative percentage of patients who reached
target HbA1c (\7.4%) in steps 1, 2, and 3. N.S. BIAsp30,
premixed insulin aspart-30/70; HbA1c, glycated hemoglo-
bin; Mix50, lispro-50/50; N.S. not signiﬁcant
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(completion of step-3) in the BIAsp 30 group. In
the Mix50n group, HbA1c levels of 9.6 ± 1.6%
at the baseline of the study were significantly
decreased to 7.8 ± 0.9% after 16 weeks
(completion of step-1), 7.6 ± 0.9% after
32 weeks (completion of step-2), and
7.7 ± 0.9% after 48 weeks (completion of step-
3). There was no significant difference in HbA1c
or FPG between the two groups at any
observation point (Table 2).
The HbA1c levels of patients who achieved
target HbA1c \7.4% significantly decreased in
each step (Table 3); however, the HbA1c levels of
patients who did not achieve target
HbA1c\7.4% were difficult to reduce regardless
of the number of insulin injections and the
insulin dosage. In addition, the fasting blood
glucose levels of uncontrolled patients did not
decrease from step 1 to step 2 in either group.
Insulin Dosage
The daily BIAsp 30 dosages for the patients who
achieved target HbA1c \7.4% in step 1 were
0.12 U/kg at the start, 0.18 U/kg at the
completion of step 1, and in step 2 were
0.14 U/kg at the start and 0.40 U/kg at the
completion of step 2, and in step 3 were 0.11 U/
kg at the start and 0.64 U/kg at the completion
of step 3. In addition, the daily BIAsp 30 doses
for the uncontrolled patients were 0.11 U/kg at
the start and 0.63 U/kg at the completion of
Table 2 Change of HbA1c, FPG, and BMI of all cases who abided by the protocol during the study
BIAsp30 Mix50 P value
HbA1c (%)
0 week 9.9 ± 1.7 (n = 36) 9.6 ± 1.6 (n = 36) 0.353
16 ± 2 week 7.8 ± 1.0* (n = 36) 7.8 ± 0.9* (n = 36) 0.978
32 ± 2 week 7.8 ± 1.2* (n = 32) 7.8 ± 0.9* (n = 32) 0.638
48 ± 2 week 8.2 ± 0.9* (n = 9) 7.7 ± 0.9* (n = 13) 0.162
FPG (mol/L)
0 week 138 ± 42 (n = 36) 130 ± 34 (n = 36) 0.400
16 ± 2 week 83 ± 24* (n = 36) 79 ± 26* (n = 36) 0.536
32 ± 2 week 83 ± 26* (n = 32) 81 ± 27* (n = 32) 0.835
48 ± 2 week 105 ± 17* (n = 9) 90 ± 26* (n = 13) 0.167
BMI (kg/m2)
0 week 24.4 ± 5.8 (n = 36) 24.5 ± 4.3 (n = 36) 0.783
16 ± 2 week 24.8 ± 5.5 (n = 36) 24.6 ± 4.2 (n = 36) 0.898
32 ± 2 week 26.0 ± 6.2 (n = 32) 24.4 ± 4.7 (n = 32) 0.343
48 ± 2 week 30.5 ± 8.3* (n = 9) 27.2 ± 7.3* (n = 13) 0.371
Values are given as mean ± SD
BIAsp30 premixed insulin aspart-30/70, BMI body mass index, FPG fasting plasma glucose, HbA1c glycated hemoglobin,
Mix50 lispro-50/50, SD standard deviation
* P\0.05 vs. the baseline data (0 week)
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step 3. The daily Mix50 dosages for the patients
who achieved target HbA1c \7.4% in step 1
were 0.11 U/kg at the start, 0.15 U/kg at the
completion of step 1, and in step 2 were 0.10 U/
kg at the start, 0.32 U/kg at the completion of
step 2, and in step 3 were 0.12 U/kg at the start,
0.56 U/kg at the completion of the step 3. In
addition, the daily Mix50 dosages for the
uncontrolled patients were 0.09 U/kg at the
start and 0.56 U/kg at the completion of step 3
(Table 3). The insulin doses between the two
groups were not significantly different in each
step.
Body Mass Index
No significant change was seen in BMI in either
group of patients who achieved target HbA1c in
step 1. BMI increased slightly but significantly
from 22.5 to 23.4 kg/m2 in BIAsp 30 patients
who achieved target HbA1c in step 2. Similarly,
the BMI increased slightly but significantly from
22.7 to 23.5 kg/m2 in Mix50 patients who
achieved target HbA1c in step 3. The BMI of
uncontrolled patients also increased
significantly in both groups (Table 3).
Moreover, the basal BMI of uncontrolled
patients was significantly higher than that of
patients who achieved target HbA1c (29.9 ± 8.0
[n = 8] vs. 22.9 ± 2.7 [n = 24] kg/m2 in BIAsp 30
group [P\0.05], 28.5 ± 6.1 [n = 6] vs.
23.4 ± 2.7 [n = 26] kg/m2 in Mix50 group,
respectively [P\0.05]).
Safety
A total of 10 hypoglycemic episodes occurred in
6 subjects (3 in BIAsp 30 group, 3 in Mix50
group). The details of hypoglycemic episodes
(BMI, HbA1c, step, treatment group, OADs,
symptom and time when hypoglycemic
episode occurred, and achieved step) are as
follows. The first case: 20.7, 7.6%, step-1, BIAsp
30, sulfonylurea (SU) and metoformin,
tachycardia and sweating, before breakfast,
step-1; the second case (2 times): 24.0, 7.8%
and 7.5%, step-2, BIAsp 30, metoformin,
sweating, 2 times before breakfast, step-2; the
third case (2 times): 25.7, 9.2% and 8.8%, step-2
and step-3, BIAsp 30, a-glucosidase inhibitor,
headache and tachycardia, before breakfast and
before dinner, uncontrolled; the fourth case:
26.0, 8.2%, step-1, Mix50, SU and thiazolidine,
sweating, before breakfast, step-2; the fifth case
(2 times): 22.5, 8.1% and 7.5%, step-2 and step-
3, Mix50, metoformin, sweating, before
breakfast and before lunch, step-3; the sixth
case (2 times): 37.8, 9.0, and 8.6%, step-2 and
step-3, Mix50, a-glucosidase and thiazolidine,
sweating and trembling, before breakfast (step-
2) and before dinner (step-3), uncontrolled. All
cases recovered by taking glucose or drinking
juice. However, there were no serious
hypoglycemic episodes during the study. In
addition, there were no adverse drug reactions
related to the BIAsp 30 or Mix50 insulin
injections.
DISCUSSION
Graber et al. [8] showed the usefulness of step-
up therapy with BIAsp 30 in a 1-2-3 study
performed in USA. They indicated that the
cumulative rates of patients achieving the
target HbA1c B6.5% and 7.0% were 21% and
41% with once-daily injection, 52% and 70%
with twice-daily injection, and 60% and 77%
with thrice-daily injection. Yoshioka et al. [10]
demonstrated the usefulness of step-up therapy
with BIAsp 30 in Japanese T2DM patients. They
showed that the cumulative rates of
achievement of HbA1c \6.5% and \7.0% were
5.1% and 21.2% with once-daily injection,
21.2% and 39.4% with twice-daily injections,
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and 28.3% and 48.5% with thrice-daily
injections (including that patients dropped
out). Recently, Hosoi et al. [14] also
demonstrated the efficacy of step-up therapy
with BIAsp 30 in Japanese patients with T2DM.
They showed that the cumulative rates of
achievement of HbA1c \7.0% were 10.3%
with once-daily injection, 41.3% with twice-
daily injections, and 51.4% with thrice-daily
injections.
Overall, the effectiveness of step-up
treatment of BIAsp 30 was recognized
regardless of ethnicity. The findings of the
present study seem to be better in terms of the
cumulative ratio of patients who achieved
target HbA1c levels than the previous Japanese
study about the treatment with BIAsp 30. A
probable explanation for the differences
between the results presented here and
previous ones is the differences of study
protocol with regard to permission for OADs
and target HbA1c levels. These findings clearly
showed the usefulness of step-up treatment by
BIAsp 30, by which 36.1% (13/36) of patients in
step 1, 43.5% (10/23) in step 2, and 11.1% (1/9)
in step 3 achieved target HbA1c \7.4%.
Moreover, the present study demonstrated
that insulin step-up treatment with Mix50
showed an effect on glycemic control equal to
that with BIAsp 30. Although more increasing
number should be needed, the ratio of patients
achieving target HbA1c in thrice-daily injection
of Mix50 (7/13: 53.8%) was better than that
with BIAsp 30 (1/9: 11.1%) (P = 0.04).
There are some merits to initiating insulin
treatment by step-up regimen using biphasic
insulin. One is that step-up treatment is a
simple method because only one insulin
device is required, and only once-daily
injection before dinner is introduced at the
start. Therefore, it is easily acceptable for not
only physicians, but also patients as a routine
clinical treatment. Previous 1-2-3 studies
demonstrated the usefulness of once-daily
injection of BIAsp 30 [8, 10]. Moreover, a
small dose of BIAsp 30 once a day before
dinner in combination with OADs was shown
to be effective for glycemic control [15, 16]. On
the other hand, there have been no reports
about once-daily injection of Mix50 before
dinner. Our findings indicated that a high rate
(36.1%) of patients achieved the target HbA1c
in not only the BIAsp 30 group but also the
Mix50 group. In addition, the insulin dosage of
patients who achieved the target HbA1c with
only once-daily injection was relatively small
(0.18 U/kg in the BIAsp 30 group and 0.15 U/kg
in the Mix50 group at the completion of step 1).
The probable explanation for the effect of once-
daily injection of Mix50 before dinner is that for
most Japanese the main meal of the day is
dinner, which has a high glycemic index since it
includes foods such as rice, as Roach et al. [17]
demonstrated that the greater proportion of
rapid-acting insulin analog was more effective
for carbohydrate-rich meals.
The prevalence of diabetes with obesity is
increasing worldwide. In general, it is difficult
to achieve target glycemic control in the
treatment of obese diabetic patients because of
high insulin resistance [18]. When insulin is
initiated in these patients, higher insulin dosage
is required and must be increased [19]. The
results of the present study show that the basal
BMI of uncontrolled patients who failed to
achieve target HbA1c \7.4% regardless of
thrice-daily injection of BIAsp 30 or Mix50
was significantly higher than that of patients
who achieved target HbA1c. During the study,
the BMI of uncontrolled patients increased
significantly in both groups. However, the rate
of increase of BMI was similar to that of a
previous study [20]. In addition, their fasting
blood glucose levels did not decrease with the
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step 2 treatment, suggesting that their insulin
resistance might be high, although plasma
c-peptide was not assessed in this study.
Lifestyle modifications with diet and exercise
are the most essential for the management of
obese diabetic patients, and combination of
OADs to decrease insulin resistance or of basal
insulin, such as glargine to decrease the fasting
blood glucose and to minimize weight gain
compared with that with rapid or premixed
insulin, should be considered when insulin
therapy is required for the treatment of obese,
diabetic patient [21].
There were several limitations in the present
study. One of the limitations was that the
diurnal plasma glucose measurement was not
performed in the outpatient setting and,
therefore, the effect of insulin treatment on
diurnal plasma glucose change was not fully
assessed. Second, the target of HbA1c \7.4%
was slightly higher than HbA1c\6.5% that the
JDS recommends as good glycemic control to
prevent microvascular complications [22].
Although a target HbA1c \7.4% was set to
minimize the number of drop-out patients in
this study, further studies with tighter and
more intensive glycemic control are needed to
elucidate the effects of step-up treatment of
BIAsp 30 and Mix50 insulin. Third, dipeptidyl
peptidase-4 (DPP-4) inhibitor, a novel anti-
diabetic agent, was not used in this study. This
is because the addition of DPP-4 inhibitor to
insulin treatment in patient with diabetes was
not permitted in the health care services in
Japan during this study period. However, some
clinical studies show that adding DPP-4
inhibitors to insulin therapy improves
glycemic control without increasing
hypoglycemia or weight gain [23, 24], and co-
treatment with DPP-4 inhibitors and insulin is
permitted in the current clinical diabetic
treatment in Japan. Therefore, increased
effectiveness of insulin step-up treatment
could be observed in patients with T2DM
with DPP-4 inhibitors in terms of
achievement of glycemic control and without
weight gain.
In conclusion, the superiority of step-up
treatment with Mix50 insulin was not
demonstrated here. However, step-up
treatment with Mix50 insulin appears to have
a clinical effect in achieving good glycemic
control equal to that of treatment with BIAsp 30
in insulin naive patient with T2DM with poor
glycemic control. This suggests that step-up
treatment by biphasic insulin is a useful
regimen to initiate insulin therapy.
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